Cosette J Serabjit-Singh
Overview
Explore the profile of Cosette J Serabjit-Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Polli J, Humphreys J, Harmon K, Castellino S, OMara M, Olson K, et al.
Drug Metab Dispos
. 2008 Jan;
36(4):695-701.
PMID: 18216274
Lapatinib [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine, GW572016, Tykerb] is a tyrosine kinase inhibitor approved for use in combination with capecitabine to treat advanced or metastatic breast cancers overexpressing HER2 (ErbB2). In this work we...
2.
Rautio J, Humphreys J, Webster L, Balakrishnan A, Keogh J, Kunta J, et al.
Drug Metab Dispos
. 2006 Feb;
34(5):786-92.
PMID: 16455806
Because modulation of P-glycoprotein (Pgp) through inhibition or induction can lead to drug-drug interactions by altering intestinal, central nervous system, renal, or biliary efflux, it is anticipated that information regarding...
3.
Thiel-Demby V, Tippin T, Humphreys J, Serabjit-Singh C, Polli J
J Pharm Sci
. 2004 Sep;
93(10):2567-72.
PMID: 15349966
The absorptive (AQ) and secretory (SQ) quotients have been proposed as a novel experimental approach to quantify the modulation of intestinal absorption and secretion by P-glycoprotein (Pgp). Because these unidirectional...
4.
Mahar Doan K, Wring S, Shampine L, Jordan K, Bishop J, Kratz J, et al.
Pharmacology
. 2004 Aug;
72(2):92-8.
PMID: 15331914
The purpose of this study was to measure the in vivo brain distribution of antihistamines and assess the influence of in vitro permeability, P-glycoprotein (Pgp) efflux, and plasma protein binding....
5.
Polli J, Baughman T, Humphreys J, Jordan K, Mote A, Webster L, et al.
Drug Metab Dispos
. 2004 Jun;
32(7):722-6.
PMID: 15205387
GV196771 [E-4,6-dichloro-3-(2-oxo-1-phenyl-pyrrolidin-3-glydenemethyl)-1H-indole-2 carboxylic acid] is a potent antagonist of the modulatory glycine site of the N-methyl-d-aspartate receptor. GV196771 has low oral bioavailability (<10%) and plasma clearance ( approximately 2 ml/min/kg)...
6.
Polli J, Baughman T, Humphreys J, Jordan K, Mote A, Salisbury J, et al.
J Pharm Sci
. 2003 Sep;
92(10):2082-9.
PMID: 14502547
Recent in vitro studies have suggested that P-glycoprotein (Pgp) and passive membrane permeability may influence the brain concentrations of non-sedating (second-generation) antihistamines. The purpose of this study was to determine...
7.
Mahar Doan K, Humphreys J, Webster L, Wring S, Shampine L, Serabjit-Singh C, et al.
J Pharmacol Exp Ther
. 2002 Nov;
303(3):1029-37.
PMID: 12438524
Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration. The objectives of this study were to determine whether there are differences in the in vitro permeability,...
8.
Wring S, Silver I, Serabjit-Singh C
Methods Enzymol
. 2002 Nov;
357:285-95.
PMID: 12424918
No abstract available.